TRPV1 and Bone Cancer Pain

Vanilloid Receptor TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders

Volumn , Issue , 2010, Pages 191-205

  Jimenez Andrade, Juan Miguel ^a   Mantyh, Patrick ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

Expression of TRPV1 in sensory nerve fibers innervating the femur; Potential activators or modulators of TRPV1 in bone cancer; TRPV1 and bone cancer pain

Indexed keywords

EID: 84889352658     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470588284.ch7     Document Type: Chapter

References (56)

1. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, Dubose RF, Cosman D, and Galibert L (1997) A homologue of the Tnf receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179.
2. Baines M and Kirkham SR (1989) Cancer pain. In Textbook of Pain (Wall PD and Melzac R, eds.), pp. 590-597. Churchill Livingstone, Edinburgh. Bassilana F, Champigny G, Waldmann R, de Weille JR, Heurteaux C, and Lazdunski M (1997) The acid-sensitive ionic channel subunit ASIC and the mammalian degenerin MDEG form a heteromultimeric H +-gated Na + channel with novel properties. J Biol Chem 272: 28819-28822.
3. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, and Seaman JJ (2001) Zoledronic acid reduces skeletal - related events in patients with osteolytic metastases. Cancer 91: 1191-1200.
4. Boyle WJ, Simonet WS, and Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337-342.
5. Brennan F, Carr DB, and Cousins M (2007) Pain management: a fundamental human right. Anesth Analg 105: 205-221.
6. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, and Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288: 306-313.
7. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, and Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389: 816-824.
8. Cherny N (2000) New strategies in opioid therapy for cancer pain. J Oncol Manag 9: 8-15.
9. ClinicalTrials.gov (2008) A Study of Tanezumab as Add-On Therapy to Opioid Medication in Patients with Pain Due to Cancer That Has Spread to Bone. Study number: NCT00545129. http://clinicaltrials.gov/ (accessed December 16, 2008).
10. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80: 1588-1594.
11. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s-6249s. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, and Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405: 183-187.
12. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, and Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405: 183-187.
13. Deigner HP and Kinscherf R (1999) Modulating apoptosis: current applications and prospects for future drug development. Curr Med Chem 6: 399-414.
14. Delaisse JM and Vaes G (1992) Mechanism of mineral solubilizationand matrix degradation in osteoclastic bone resorption. In Biology and Physiology of the Osteoclast (Rifkin BR and Gay CV, eds.), pp. 289-314. CRC, Ann Arbor, MI.
15. Foley KM (1995) Misconceptions and controversies regarding the use of opioids in cancer pain. Anticancer Drugs 6: 4-13.
16. Fulfaro F, Casuccio A, Ticozzi C, and Ripamonti C (1998) The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78: 157-169.
17. Ghilardi JR, Rohrich H, Lindsay TH, Sevcik MA, Schwei MJ, Kubota K, Halvorson KG, Poblete J, Chaplan SR, Dubin AE, Carruthers NI, Swanson D, Kuskowski M, Flores CM, Julius D, and Mantyh PW (2005) Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25: 3126-3131.
18. Griffiths JR (1991) Are cancer cells acidic? Br J Cancer 64: 425-427.
19. Guo A, Vulchanova L, Wang J, Li X, and Elde R (1999) Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 11: 946-958.
20. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V, and Expert Working Group of the Research Network of the European Association for Palliative C (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587-593.
21. Honore P, Chandran P, Hernandez G, Gauvin DM, Mikusa JP, Zhong C, Joshi SK, Ghilardi JR, Sevcik MA, Fryer RM, Segreti JA, Banfor PN, Marsh K, Neelands T, Bayburt E, Daanen JF, Gomtsyan A, Lee CH, Kort ME, Reilly RM, Surowy CS, Kym PR, Mantyh PW, Sullivan JP, Jarvis MF, Faltynek CR (2009) Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 142(1-2): 27-35.
22. Horton A, Nesbitt S, Bennett J, and Stenbeck G (2002) Integrins and other cell surface attachment molecules of bone cells. In Principles of Bone Biology (Bilezikian JP, Raisz LG, and Rodan GA, eds.), pp. 265-286. Academic Press, San Diego, CA.
23. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
24. Julius D and Basbaum AI (2001) Molecular mechanisms of nociception. Nature 413: 203-210.
25. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, and Jun S (2008) Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 14: 6690-6696.
26. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, and Jun S (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25: 4431-4437.
27. Luger NM, Honore P, Sabino MAC, Schwei MJ, Rogers SD, Mach DB, Clohisy DR, and Mantyh PW (2001) Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 61: 4038-4047.
28. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, Rathbun M, Clohisy DR, Honore P, Yaksh TL, and Mantyh PW (2002) Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 99: 397-406.
29. Major PP, Lipton A, Berenson J, and Hortobagyi G (2000) Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 88: 6-14.
30. Mantyh PW (2006) Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 7: 797-809.
31. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69: 1-18.
32. Mercadante S and Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24: 425-432.
33. Mercadante S and Fulfaro F (2007) Management of painful bone metastases. Curr Opin Oncol 19: 308-314.
34. Niiyama Y, Kawamata T, Yamamoto J, Furuse S, and Namiki A (2009) SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br J Anaesth 102: 251-258.
35. Olson TH, Riedl MS, Vulchanova L, Ortiz-Gonzalez XR, and Elde R (1998) An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats. Neuroreport 9: 1109-1113.
36. Portenoy RK (1999) Managing cancer pain poorly responsive to systemic opioid therapy. Oncology 13: 25-29.
37. Portenoy RK and Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41: 273-281.
38. Portenoy RK and Lesage P (1999) Management of cancer pain. Lancet 353: 1695 - 1700.
39. Rodan GA and Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289: 1508-1514.
40. Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, Peters CM, Rogers SD, Schwei MJ, de Felipe C, and Mantyh PW (2002) Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62: 7343-7349.
41. Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, Boustany L, Shelton DL, and Mantyh PW (2005) Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115: 128-141 Sevcik MA, Luger NM, Mach DB, Sabino MA, Peters CM, Ghilardi JR, Schwei MJ, Rohrich H, De Felipe C, Kuskowski MA, and Mantyh PW (2004) Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 111: 169-180.
42. Sevcik MA, Luger NM, Mach DB, Sabino MA, Peters CM, Ghilardi JR, Schwei MJ, Rohrich H, De Felipe C, Kuskowski MA, and Mantyh PW (2004) Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 111: 169-180.
43. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, L ü thy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, and Boyle WJ (1997) Osteoprotegerin-a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
44. Singh AS and Figg WD (2005) In vivo models of prostate cancer metastasis to bone. J Urol 174: 820-826.
45. Stewart B and Kleihues P (2003) World Cancer Report. IARCS Press, Lyon, France.
46. Sutherland S, Cook S, and EW M (2000) Chemical mediators of pain due to tissue damage and ischemia. Prog Brain Res 129: 21-38.
47. Teitelbaum SL (2007) Osteoclasts: what do they do and how do they do it? Am J Pathol 170: 427-435.
48. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, and Julius D (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21: 531-543.
49. Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Miki K, Yonenobu K, Ochi T, and Noguchi K (2000) Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury. Mol Cell Neurosci 15: 170-182.
50. van den Beuken-van Everdingen M, de Rijke J, Kessels A, Schouten H, van Kleef M, and Patijn J (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18: 1437-1449.
51. Weber M and Huber C (1999) Documentation of severe pain, opioid doses, and opioid - related side effects in outpatients with cancer: a retrospective study. J Pain Symptom Manage 17: 49-54.
52. Woolf CJ and American College of Physicians, and American Physiological Society (2004) Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140: 441-451.
53. Woolf CJ and Salter MW (2000) Neuronal plasticity: increasing the gain in pain. Science 288: 1765-1769.
54. World Health Organization (WHO) (2009) Cancer Control. http://www.who.int/ cancer/en/ (accesed May 12, 2009).
55. Yamamoto J, Kawamata T, Niiyama Y, Omote K, and Namiki A (2008) Down - regulation of mu opioid receptor expression within distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. Neuroscience 151: 843-853.
56. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, and Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Sci U S A 95: 3597-3602.